Protective effects of coffee consumption on HIV & HCV co-infected patients
A research team ( Inserm Unité 912, SESSTIM, Marseille et Unité 1219, Bordeaux) support by the ANRS studied for the first time in the context of the ANRS HEPAVIH prospective cohort is the first to investigate the relationship between coffee consumption and the risk of all-cause mortality in HIV-HCV co-infected patients. Indeed, coffee is known to have anti-inflammatory properties. In the general population, drinking three or more cups of coffee a day has been found to be associated with a 14% reduction in the risk of all-cause mortality. The ANRS study used data from a five-year follow-up of 1,028 HIV-HCV co-infected patients enrolled in the French national ANRS HEPAVIH cohort. At enrolment, one in four patients reported drinking at least three cups of coffee daily. Analysis showed that drinking at least three cups of coffee daily was associated with a 50% reduction in mortality risk even after taking into account HCV clearance, HIV- and HCV-related factors, and other sociobehavioral factors, such as having a steady partner and not smoking. This research suggests the importance of behaviors on reduced mortality risk. As Patrizia Carrieri said in the press release about their work presented at the IAS conference in 2017 “ further studies are needed on the interactions between eating behaviors, consumption of psychoactive substances, and liver disease progression, particularly interventional studies. The ANRS HEPAVIH cohort data obviously cannot be used to recommend the consumption of any substance or product to HIV/HCV co-infected patients. However, it would certainly be useful for clinicians to take into account their patients’ consumption behaviors when making a clinical evaluation."